Form 4: BioCryst Pharmaceuticals Executive Helen M. Thackray Reports Share Withholding for Tax Obligations
SEC Form 4 Filing
Helen M. Thackray, Chief R&D Officer of BioCryst Pharmaceuticals, reports the withholding of 7,525 common stock shares to cover tax obligations related to vesting Restricted Stock Units on March 31, 2025.
Summary
- On March 31, 2025, Helen M. Thackray, Chief R&D Officer of BioCryst Pharmaceuticals, had 7,525 shares of common stock withheld by the issuer to satisfy tax obligations.
- The withholding occurred in connection with the vesting of previously granted Restricted Stock Units.
- The price per share for the withholding was $7.5.
- Following the transaction, Thackray directly owns 377,318 shares of BioCryst Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to insider transactions, indicating a neutral sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a standard tax obligation fulfillment related to equity compensation.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of the transaction (share withholding for tax obligations). |
| 04/02/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, BioCryst Pharmaceuticals, BCRX, Helen M. Thackray, Chief R&D Officer, Share Withholding, Restricted Stock Units, Tax Obligations, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.